ライフサイエンスコーパス: agent

1 ntial of (99m)Tc-PSMA-I&S as a SPECT imaging agent.

2 on by activation of an achiral sulfenylating agent.

3 e not significantly associated with contrast agent.

4 introducing phenanthroline as a pore-forming agent.

5 ing therapeutics and diagnostics in the same agent.

6 abled treatment with a new-targeted systemic agent.

7 ddition to serving as an ultrasound contrast agent.

8 of garcinol as a therapeutic pharmacological agent.

9 in to be the precursor-induced antimicrobial agent.

10 inical development of 3E10 as an anti-cancer agent.

11 ive to the anti-proliferative effects of the agent.

12 ses that have yet to be assigned a causative agent.

13 min and then bonded with the primer-bonding agent.

14 uced using a clinically-relevant iso-osmotic agent.

15 and renders cells sensitive to DNA damaging agents.

16 ignancies) or c-MPL-targeted pharmacological agents.

17 fety and the move away from chemical control agents.

18 gher than those of gadolinium-based contrast agents.

19 hybrids can serve as potential anti-leukemia agents.

20 xperimental frontline trials exploring novel agents.

21 acious than currently commercially available agents.

22 MT dynamics in the design of new therapeutic agents.

23 s as novel antitrypanosomal and antimalarial agents.

24 andiamide or cyanamide) as shape controlling agents.

25 synthetic route to these important bioactive agents.

26 making them effective TLR-9 immunomodulatory agents.

27 py-costly process using tailored stabilizing agents.

28 uencing to predict the efficacy of anti-HER2 agents.

29 overcome drug resistance to single targeting agents.

30 disease and/or neurotoxic immunosuppressant agents.

31 tifying exposure to unknown organophosphorus agents.

32 geted by subsequent exposure to DNA damaging agents.

33 as targets for new antibacterial therapeutic agents.

34 llow the future testing of novel therapeutic agents.

35 target for the development of new anti-viral agents.

36 struction of pharmaceutical and agrochemical agents.

37 s well as aromatic-containing pharmaceutical agents.

38 nds as promising candidates as antiparasitic agents.

39 susceptible to narrow-spectrum antimicrobial agents.

40 r SIC with control and specific occupational agents.

41 ith prednisone and/or glucocorticoid-sparing agents.

42 timalarial, anticancer, and immunomodulatory agents.

43 es the metabolic response to drugs and toxic agents.

44 hese compounds as potential immunomodulatory agents.

45 significantly modulates the efficacy of such agents.

46 be eliminated by adding appropriate reducing agents.

47 o develop practical total syntheses of these agents.

48 hether these effects differ across anti-VEGF agents.

49 s or intrinsic apoptosis by chemotherapeutic agents.

50 fully reversible by treatment with reducing agents.

51 ethyl donor, and by reaction with alkylating agents.

52 olizumab) and the anti-tumor necrosis factor agents.

53 sorders and the testing of novel therapeutic agents.

54 or the highly selective sigma-1 receptor PET agent (18)F-6-(3-fluoropropyl)-3-(2-(azepan-1-yl)ethyl)b

55 or in combination with the DNA-demethylating agent 5-aza-2'-deoxycytidine (DAC).

56 vity of cancer cells to the chemotherapeutic agent 5-fluorouracil.

57 se inhibitors (CHKi) exhibit striking single-agent activity in certain tumors, but the mechanisms acc

58 carry and selectively release antimicrobial agents after attachment or within oral biofilms, resulti

59 with temozolomide, a clinical DNA-alkylating agent against glioma, 6OTD required lower concentrations

60 ive targets for the development of antiviral agents against chronic HBV infection.

61 for the primary use of mTORis as protective agents against most other cancer types.

62 cterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma.

63 This model can be used to test therapeutic agents aimed at chemoprevention.

64 sed ink containing a reversible crosslinking agent, ammonium persulfate.

65 s have been proposed: movement of a chemical agent and a pressure wave through the vasculature.

66 ay increase the potency of this chemotherapy agent and allow for reduced systemic doses.

67 are limited by the half-life of the contrast agent and challenges in accurate control of large volume

68 parib in combination with a chemotherapeutic agent and provides a foundation for future studies in th

69 response rates of current immunotherapeutic agents and achieve responses to the cancers that are ref

70 licating the evaluation of new immunotherapy agents and customizing treatment for individual patients

71 r the design of new RXRalpha-based antitumor agents and drug combinations.

72 ntraperitoneal targeting of other anticancer agents and nanoparticles using peptides and other affini

73 ticular focus on individual chemotherapeutic agents and solid cancer risk.

74 he acceptable range for clinical PET imaging agents and the potential for translation into human pati

75 oncentrations for anti-tumor necrosis factor agents and thiopurines to inform clinical decision makin

76 (with interferon then with direct antiviral agents) and underwent an ultrasound examination every 6

77 opic, syngeneic model, when used as a single agent, and more so when used in combination with cisplat

78 promising target for herbicides, antifungal agents, and antibiotics.

79 drug carriers, radiosensitizers and imaging agents, and characterizing nanoparticle biodistribution

80 ment duration, requirement for combinatorial agents, and extent of efficacy.

81 f in bioactive natural products, therapeutic agents, and molecular catalysts, motivating the continui

82 tion proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies.

83 ion sensitizes cells to a number of chemical agents, and mutations at predicted channel-facing positi

84 w drugs, both antiplatelet and anticoagulant agents, and new coronary stents will continue the journe

85 ase, assess tumour resistance to therapeutic agents, and potentially screen individuals for the early

86 nonlinear optical materials, MRI contrasting agents, and sensitizers for photodynamic therapy (PDT);

87 ptable safety profile and evidence of single-agent antimyeloma activity in patients with relapsed/ref

88 se 2 trials for (18)F-TFB as an hNIS imaging agent are warranted.

89 rapies with all-oral direct-acting antiviral agents are associated with high rates of sustained virol

90 This supports the idea that anti-VEGF agents are effective in reducing the amount of VEGF pres

91 The main causative agents are enterovirus 71 (EV71), coxsackievirus A16 (CV

92 Survival data with direct-acting antiviral agents are not available.

93 In the event of a pandemic, antiviral agents are the mainstay for treatment, but broadly neutr

94 her poor prognostic factors, hypomethylating agents are the preferred option, even though their impac

95 tiation has arrived at natural product-based agents as an important class of modulators.

96 ction frequencies at follow-up were for most agents as high as at baseline, because new infections ha

97 pore-former, hydrophilizing and antifouling agent, as well as an enhancer to the mechanical and reje

98 risk for liver toxicity by the anti-leukemic agent asparaginase, but the mechanism is unknown.

99 dynamic Abeta oligomers are the main causal agent associated with the onset of AD.

100 certain blood cancers and a variety of other agents at different stages of development.

101 show that the dynamics of an anthrax-causing agent, Bacillus cereus biovar anthracis, in a tropical r

102 e approach integrates cellular behaviors via agent-based modeling (ABM) and hemodynamic effects via c

103 based on the principles of cellular automata/agent-based modeling and combine it with very detailed e

104 An agent-based stochastic simulation model of P. falciparum

105 Doxorubicin is a highly effective anticancer agent but causes cardiotoxicity in many patients.

106 tes in a manner similar to other antiseizure agents but with slower kinetics of binding and unbinding

107 elium is a principal site for detecting such agents, but precisely how it communicates with neural el

108 roorganisms and may be useful as therapeutic agents by degrading biofilms and attenuating virulence.

109 ococcus aureus is the most common infectious agent causing pyogenic spondylodiscitis.

110 ified the approved small-molecule antifungal agent ciclopirox as a novel pan-histone demethylase inhi

111 The combination of antifungal agents (cinnamon bark oil, zinc gluconate and trans-feru

112 l-established anthracycline chemotherapeutic agent commonly used in the treatment of a wide range of

113 tors, including approved and investigational agents, comparing ex vivo responses of primary AML cells

114 downstream mediator of newer pharmacological agents currently under investigation for treating psychi

115 plant population but direct acting antiviral agents (DAA) provide an effective cure of HCV infection

116 regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options.

117 re incubation and the addition of antifungal agents decreased growth of Candida species in optisol-GS

118 The two-agent delivery system presented here possesses notable b

119 ical trials have investigated the effects of agents designed to target distinct levels of the IL23 an

120 rmined 1,200 mg to be the recommended single-agent dose for future studies in FL and DLBCL, with 800

121 e selected the somatostatin receptor imaging agent DOTATOC as the foundation for developing a dual-la

122 diac and respiratory motion phases, contrast-agent dynamics, and blood flow velocity fields.

123 and many patients become resistant to these agents early in the course of their disease.

124 The most successful trapping agents employed to catch these fleeting intermediates ar

125 digital (FFD) mammography, dynamic contrast agent-enhanced (DCE) magnetic resonance (MR) imaging, an

126 To exploit this dual concept, we developed agents exerting partial FXR agonism and sEH inhibitory a

127 with a fluorinated pyrimidine and a platinum agent, followed by later treatment with taxanes and irin

128 The potential of (18)F-FTC-146 as an imaging agent for a variety of neuroinflammatory diseases is cur

129 ishes hyperpolarized [(13)C]-Glyc as a novel agent for clinically relevant (13)C MRS studies of energ

130 or in HD mice, thus constituting a promising agent for HD neuroprotective treatment.

131 rypanosoma brucei (T. brucei), the causative agent for human African trypanosomiasis (HAT) or sleepin

132 hibitor SCH772984 as a potential therapeutic agent for primary liver cancer.

133 s establish 15D11 as a potential therapeutic agent for the prevention or treatment of bone metastasis

134 phate acts effectively as a reversible redox agent for the regeneration of the dye.

135 ts that Myr might be a potential therapeutic agent for the treatment of DCM.

136 focus on discovering an acute antithrombotic agent for use in a hospital setting.

137 nanoparticles are explored as image contrast agents for both superlocalization and super-resolution i

138 imultaneously offering a source of oxidizing agents for combustion of reactive nanomaterials.

139 acid sequestrants only as optional secondary agents for consideration in patients intolerant to ezeti

140 rol is heavily dependent on chemotherapeutic agents for disease prevention and drug treatment.

141 ide ligands and directly encapsulate medical agents for enhanced drug delivery.

142 itors (BETi) represent promising therapeutic agents for metastatic melanoma, yet their mechanism of a

143 acin and linezolid were tested as comparator agents for MIC and DD methods, respectively.

144 tterns of use and relative risks of systemic agents for moderate to severe psoriasis in children.

145 creation of more potent biological delivery agents for research and biomedical applications.

146 functionalized IONPs are promising contrast agents for stem cell tracking by T2-weighted MRI as they

147 NT3A, where WNT3A antagonists could be novel agents for the treatment of metastasis and for skeletal

148 and distribution of effective antimicrobial agents for treatment and postexposure prophylaxis.

149 A limited number of antifungal agents from only a few drug classes are available to tre

150 of the macrocyclic gadolinium-based contrast agent (GBCA) gadoterate meglumine on the signal intensit

151 ons of macrocyclic gadolinium-based contrast agents (GBCAs) on the signal intensity (SI) of the denta

152 train FCMs, which combines a dynamical multi-agent genetic algorithm (dMAGA) with the decomposition-b

153 clophosphamide (PTCy) can function as single-agent GVHD prophylaxis after myeloablative, HLA-matched

154 No therapeutic agent has been approved for the prevention or treatment

155 Currently, no single therapeutic agent has been identified as synthetically lethal with S

156 Although the introduction of novel targeted agents has improved patient outcomes in several human ca

157 Second, 6 second-line new agents have been recently developed and offer new possib

158 le Magnetic Resonance Imaging (MRI) contrast agents have been widely used to provide critical assessm

159 light chains combined with novel antimyeloma agents have not been evaluated prospectively.

160 h synthetic convenience, indicate that these agents have potential in membrane protein research.

161 udy applied a three-dimensional dynamic dual-agent hyperpolarized (13)C magnetic resonance spectrosco

162 ics that enable identification of infectious agents improve patient outcomes, antimicrobial stewardsh

163 ntration of a gadolinium-containing contrast agent in a region of interest, thereby allowing the rete

164 external application of an anti-inflammatory agent in animals.

165 5-HT is an important pro-kinetic agent in the colon.

166 cabozantinib would be considered a promising agent in this patient population.

167 ight oligomers that can act as a therapeutic agent in vitro and in vivo.

168 ung TH17 inflammation requires environmental agents in addition to antigen and to identify the lung a

169 fully assessed when investigating biological agents in combination and should never be done outside o

170 amycin in conjunction with T cell-activating agents in HIV-1 cure strategies.

171 (EVs) are among the most frequent infectious agents in humans worldwide and represent the leading cau

172 it is important to test for other infectious agents in parallel, as cross-reactivity can occur.

173 approach in the design of novel therapeutic agents in preference to compounds targeting a single rec

174 on of reporter molecules and surface-binding agents in specific locations, which have been recently e

175 The use of neuroprotective agents in stroke has been a notable failure of translati

176 tely 44% of patients received antineoplastic agents in the last 30 days of life throughout the study

177 in productive replication of the infectious agents in the recipient cell.

178 ogrel with ticagrelor, a potent antiplatelet agent, in patients with peripheral artery disease.

179 The implicated agents included amoxicillin/clavulanate (n = 3), temozol

180 ver, insensitivity to these chemotherapeutic agents including cisplatin is common.

181 al characteristics for targeted MRI contrast agents, including high relaxivity, unappreciable sedimen

182 eptor DC-SIGN by numerous chronic infectious agents, including Porphyromonas gingivalis, is shown to

183 These studies revealed that the agent inhibited pERK1/2 phosphorylation in all tumours,

184 lansoprazole as a potential antituberculosis agent is warranted.

185 tic gold nanoclusters (MGNCs) as the etching agents is described.

186 When a sample mixed with chaotropic agents is filtered through the nucleic acid isolation me

187 and unambiguous identification of biothreat agents is of paramount importance for confirmation of th

188 ecular mechanisms triggered by these various agents is poorly understood, but it might explain the di

189 Cellular contact with most damaging agents is reduced by the action of the mucociliary appar

190 dogyne incognita with the biological control agent KM2501-1 resulted in a mortality of 87.66% in vitr

191 f humans interacted with autonomous software agents (known as bots).

192 s that harbor bacterial, viral and parasitic agents like Bartonella sp., Phleboviruses and Leishmania

193 Development of pharmacological agents like NACA may eventually prevent cataract formati

194 ynergistic combinations of latency reversing agents (LRAs), such as histone deacetylase (HDAC) inhibi

195 These agents may be part of doublet or triplet combinations, o

196 The causative agent, measles virus, is a small enveloped RNA virus tha

197 The poor performance of single-agent melphalan in this setting prompted us to study a n

198 ith systemic infusion of ultrasound contrast agent microbubbles (MB) causes localized blood-brain bar

199 ive was to test the mitochondrially targeted agent, MitoQ, alone and in combination with first line t

200 acked BSACI compliant neuromuscular blocking agent (NMBA) panels and 17/44 (39%) lacked a NAP6-define

201 kade with programmed death 1 (PD-1) targeted agents, novel immunotherapies and combinations likely wi

202 mia virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemia (ATL) and HTLV-1-associat

203 described baseline testing for the causative agent of AIDS, the human immunodeficiency virus (HIV).

204 is a New World (NW) arenavirus and causative agent of Bolivian hemorrhagic fever (HF).

205 these is Streptococcus mutans, the causative agent of dental caries, the most prevalent childhood dis

206 ns, including Anaplasma phagocytophilum, the agent of human granulocytic anaplasmosis.

207 r KS tumors.IMPORTANCE KSHV is the etiologic agent of Kaposi's sarcoma, the most common tumor of AIDS

208 Coxiella burnetii is the causative agent of Q fever, a zoonotic disease that threatens both

209 Trypanosoma brucei, the causative agent of sleeping sickness (Human African Trypanosomiasi

210 o compare energy metabolism in the causative agent of sleeping sickness, Trypanosoma brucei, with tha

211 m oxysporum f. lycopersici (Fol), the causal agent of tomato wilt disease, produces effector protein

212 acterium tuberculosis (Mtb) is the causative agent of tuberculosis, which kills 1.8 million annually.

213 Francisella tularensis, the etiological agent of tularemia, is one of the most infectious bacter

214 ion-making, and health workers are important agents of behavior change.

215 e like the parainfluenza viruses, as well as agents of lethal encephalitis like Nipah virus.

216 Plasmodium parasites, the causative agents of malaria, have evolved a unique cell division c

217 ut these phenomena, especially the causative agents of many coral diseases.

218 of mast cells and basophils, with release of agents of the allergic response, ensues when multivalent

219 oquinone (ABQ) library against the causative agents of trypanosomiasis, and cutaneous leishmaniasis,

220 1.5, 3, and 7 T) and the effect of contrast agent on DNA double-strand-break (DSB) formation in pati

221 ition of inulin as a surfactant or stability agent on white compound chocolate sweetened with sucralo

222 nantioselective synthesis of the preclinical agent OPC 51803.

223 seamless transition to alternative targeted agents, patients progressing with CLL were continued on

224 from 2013 to 2014 were analyzed by anti-VEGF agent, payment category, and dollar amount.

225 x) were co-loaded with a nanobubble contrast agent (perfluoropentane, PFP) using a one-step sonoporat

226 0%) were comparable to that of the reference agent PF-04937319 ( 154%).

227 demonstrate in vitro susceptibility to these agents, potentially affording additional treatment oppor

228 e sex, filling beta-blocker and antiplatelet agent prescriptions, and attending cardiac rehabilitatio

229 rating that the intercalation of the capping agent promotes oxidation of the silver core, occurring a

230 roposed that can be adapted to the suspected agent, purpose of diagnosis and available resources.

231 exposed to endogenous and exogenous damaging agents, representing a significant challenge to genome s

232 Addition of reducing and oxidizing agents respectively increased and decreased dough height

233 ial, and nonmicrobial (toxins and irritants) agents, resulting in production of many different solubl

234 ns to FCs is identification of the offending agent(s), which is based on careful dietary history taki

235 comparing ClBcat with BCl3 as an activating agent showed why BCl3, in contrast to ClBcat, failed to

236 g the hydrolysis of a chemical warfare nerve agent simulant over a polyoxometalate catalyst.

237 Using a set of chemical warfare agent simulants with nominally the same reduced mobility

238 y antibodies, requiring the use of bypassing agents such as factor VIIa and factor concentrates.

239 nd catalytic degradation of chemical warfare agents such as sarin and sulfur mustard using metal-orga

240 tivation and management of highly infectious agents, such as acid-fast bacilli and systemic fungi, we

241 quantitation of a phosphoryl fluoride nerve agent surrogate.

242 tic targets in breast and gastric cancer but agents targeting Her2 have not yet demonstrated anti-tum

243 ime of food intake is emerging as a dominant agent that affects circadian clocks in metabolic organs.

244 ical great potential as a versatile reducing agent that can be generalized in other metallic nanowire

245 ve recently discovered a novel pharmacologic agent that combines a NEP inhibitor and an angiotensin r

246 1,25D appears as an interesting therapeutic agent that inhibits the IL-23 receptor pathway, providin

247 quires the addition of an exogenous contrast agent that may have limited tissue access.

248 CPI-613 is a novel anticancer agent that selectively targets the altered form of mitoc

249 healing of compromised membranes via healing agents that are added to the feed side of a membrane sys

250 ering from chronic pain, and new therapeutic agents that are more effective, safer, and devoid of abu

251 xperience recurrent exposure to inflammatory agents that catalyze fluctuations in the concentrations

252 Prions are infectious agents that cause neurodegenerative diseases such as Cre

253 ions or PrP(Sc) are proteinaceous infectious agents that consist of misfolded, self-replicating state

254 new route for the development of anticancer agents that could suppress KRAS expression.

255 and therapeutic approaches, with a focus on agents that have been clinically adopted.

256 erscore the importance of hosts as selective agents that shape emergent symbiont populations.

257 e screened the FDA-approved drug library for agents that share significant similarity in 3D shape and

258 strategies that combine MEK inhibitors with agents that target apoptotic pathways may be a promising

259 Further study is required to test effects of agents that target the NO pathway in reducing arterial s

260 th alkyl halides or sulfonates as alkylating agents, the use of unactivated olefins for alkylations h

261 ed chemotherapy, the most widely used single-agent therapy for pancreatic cancer.

262 aturated imines that are potent DNA damaging agents, thereby confirming an earlier mechanism of actio

263 ssium hydride as a redox-controlled reducing agent to access the PAH dianions, and so enables the det

264 sozyme (Lys), was selected as the biological agent to be immobilized.

265 by allowing the retention or clearance of an agent to be quantified.

266 explanation is the lack of capacity of this agent to penetrate the central nervous system.

267 for fine-tuning reaction mixtures of various agents to enhance the overall activity of a cocktail of

268 significant clinical need for new antifungal agents to manage infections with pathogenic species such

269 testinal microbiota with prebiotics or other agents to prevent or treat obesity.

270 Use of these agents to reduce fragility fractures in patients with lo

271 valent attachment of amino acid deactivation agents to residual activated carboxy groups of pCB.

272 ACTs) have been widely adopted as first-line agents to treat uncomplicated falciparum malaria due to

273 drates, both KCl and NaCl act as salting-out agents towards trehalose, as seen in the elevated activi

274 (AraC) represents the most effective single agent treatment for AML.

275 oad range of fungi, including the biocontrol agent Trichoderma atroviride, the plant pathogens Fusari

276 Here we identify anti-VEEV agents using in silico structure-based-drug-design (SBDD

277 able wireless tattoo and textile-based nerve-agent vapor biosensor systems offer considerable promise

278 ning regarding personal exposure to OP nerve-agent vapors in variety of decentralized security applic

279 ribed here can help promote the use of these agents versus vancomycin by effectively designing their

280 thioamides with robust dioxazolone amidating agents via C(sp(3) )-H bond activation to generate the d

281 zed metabolites that includes the anticancer agent vincristine, antimalarial quinine and neurotoxin s

282 de to provide even more potent antimicrobial agents [VRE minimum inhibitory concentration (MIC) = 0.0

283 increased to a great extent when a chelating agent was added.

284 Extravasation of the contrast agent was defined as anastomotic leakage.

285 low with the use of a water-soluble contrast agent was performed on the 5(th) postoperative day.

286 e compounds in comparison with the reference agent was studied using molecular docking.

287 nsignificant case cohort use among cytotoxic agents was found for exposure to cyclophosphamide (OR, 3

288 In an effort to identify new antidiabetic agents, we have discovered a novel family of (5-imidazol

289 Ang II plus BIM (for 2 h), after which these agents were removed and contractility measurements perfo

290 New bifunctional phase transfer agents were synthesized and investigated for their abili

291 various gene deletions or chemical blocking agents were tested by investigating the expression of PG

292 Afterglow optical agents, which emit light long after cessation of excitat

293 ion of ROR1, indicating that combining these agents, which target ROR1 and Bcl2, may have additive, i

294 ts are used to predict whether an antifungal agent will be clinically effective against a particular

295 Vitamin D is an environmental and dietary agent with known anticarcinogenic effects, but protectio

296 tion of probiotics, vitamins, and biological agents with AIT is highlighting current advances.

297 Only trials investigating agents with an approved indication of reperfusion therap

298 mically modulating signals from the contrast agents with an external near-infrared optical stimulus,

299 seful for the development of future delivery agents with improved properties.

300 te oral, injectable, or infusible anticancer agent within 90 days.